Filana Therapeutics (FLNA)

• Market cap: $42.7M
• 1 day: -1.72%
• 5 days: -13.25%
• 1 month: -27.47%
• 3 months: -43.28%
• 6 months: -56.62%
• Year to date: -57.66%
• 1 year: -62.82%
• 5 years: -99.35%
• 10 years: -95.34%
• Sector: Healthcare
• Industry: Biotechnology

About: Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.

Employees: 20